Selected Mesenchymal Stromal Cells to Reduce Inflammation in Patients With PSC and AIH

Exclusion Criteria

• •6. Patients must be on standard-of-care AIH treatment for ≥ 24 weeks -this includes any AIH therapy except biologics
• •7. Stable doses of immunosuppression for a minimum period of 4 weeks (28 days) at the time of Visit 1.
• •1. Refusal or lacks capacity to give informed consent to participate in trial
• •2. Patient who is unable to participate in follow-up assessment
• •3. Participation actively, or within 5 half-lives, of another interventional clinical trial
• •4. Known hypersensitivity to the investigational product or any of its formulation excipients
• •5. Evidence of active malignancy (within 3 years of Visit 1), other than non-melanomatous skin cancer and cervical dysplasia in situ
• •6. Major surgical procedure within 30 days at Visit 1
• •7. Prior organ transplantation
• •8. Active harmful alcohol consumption as evaluated and documented by the Investigator
• •9. Poor venous access, therefore unable to support a 22G needle for infusion
• •10. Creatinine \> 133 μmol/L or being treated with renal replacement therapy at the time of Visit 1
• •11. AST or ALT \> 10 x ULN
• •12. ALP \> 10 x ULN
• •13. Platelets \< 50 x 10\^9/L
• •14. Total Bilirubin \> 2 x ULN
• •15. INR \> 1.3 (in the absence of concomitant use of Warfarin or equivalent anti-coagulant therapy)
• •16. Albumin \< 35 g/L
• •17. Haemoglobin \< 10 g/dL
• •18. Past or present evidence of decompensated chronic liver disease:
• •1. Radiological or clinical evidence of ascites
• •2. Hepatic encephalopathy
• •3. Endoscopic evidence for portal hypertensive bleeding
• •19. Any active treatment with biologic therapy (monoclonal antibodies)
• •20. Clinically severe cardiovascular disease as evaluated by the Investigator
• •21. Pregnancy or breast-feeding
• •22. Women of child bearing potential who are unwilling to practice effective contraception (i.e. barrier, oral contraceptive pill, implanted contraception, or previous hysterectomy, bilateral oophorectomy) for the duration of the trial up to 90 days after the trial drug is administered. If using hormonal agents the same method must have been used for at least 1 month before trial dosing and patients must use a barrier method during that time period
• •23. Non-vasectomised men, sexually active with women of child bearing potential, who are not willing to practice effective contraception (condom with spermicide) for the duration of the trial up to 90 days after the trial drug is administered
• •24. Patients with a history of hepatitis C (present or past infection), known positivity for antibody to HIV or any evidence of current or past hepatitis B infection
• •25. Presence of an acute/chronic infection or illness that, at the discretion of the Investigator, might compromise the patient's health and safety in the trial
• •26. Any symptoms indicative of Covid-19; including fever, chronic/persistent cough, or loss of sense of taste or smell in the preceding two weeks.
• •27. Receipt of live vaccination within six weeks prior to Visit 1
• •1. Documented alternative aetiology for sclerosing cholangitis (i.e. secondary sclerosing cholangitis)
• •2. A dominant (as determined by Investigator) alternative chronic or active liver injury other than PSC at the time of Visit 1; Patients with possible overlap syndrome with AIH are excluded from the PSC cohort if the Investigator considers AIH as the dominant liver injury
• •3. UDCA dose modification within the last 90 days
• •4. ALP \> 10 x ULN
• •5. Evidence of cholangitis within 90 days of Visit 1
• •1. Documented evidence of cholangitis by physician
• •2. Need for any antibiotics for presumed cholangitis
• •6. Any patient taking prophylactic antibiotics to combat recurrent cholangitis
• •7. Presence of percutaneous biliary drain, or internal biliary stent
• •8. Diagnosed hepatocellular carcinoma or cholangiocarcinoma or high clinical suspicion thereof
• •9. Dominant stricture clinically suspicious of cholangiocarcinoma (as determined by Investigator)
• •1. Unstable disease as evidenced by:
• •2. Requirement for daily prednisolone \> 10mg
• •3. Mayo Clinic Score ≥ 2 (see Appendix 1 for details) AND clinician assessment of active disease requiring up-titration of treatment; last colonoscopy within last year used for endoscopic component
• •2. Any colonoscopic evidence of clinically significant dysplasia at last colonoscopy
• •3. Patients who have not had their routine colonoscopy within 24 months prior to planned MSC infusion and are unable to have their screening colonoscopy examination as per standard care prior to Visit 3
• •4. A Mayo score/ Disease Activity Index for Ulcerative Colitis of ≥ 5 (https://www.mdcalc.com/mayo-score- disease-activity-index-dai-ulcerative-colitis)
• •1. A dominant (as determined by Investigator) alternative chronic or active liver injury other than AIH at the time of Visit 1; Patients with possible overlap syndrome with PSC are excluded from the AIH cohort if the Investigator considers PSC as the dominant liver injury
• •2. AST or ALT \> 10 x ULN
• •3. Patients on a prednisolone dose of \> 20 mg at the time of screening
• •4. Treatment with biologic therapy within 24 weeks of the time of screening
• •5. Patients with a history of poor compliance with medication
• •6. Diagnosed hepatocellular carcinoma or cholangiocarcinoma or high clinical suspicion thereof